Download Gene Section ELF4 (E74-like factor 4 (ets domain transcription factor))

Atlas of Genetics and Cytogenetics
in Oncology and Haematology
INIST-CNRS
OPEN ACCESS JOURNAL
Gene Section
Review
ELF4 (E74-like factor 4 (ets domain
transcription factor))
Stephen D Nimer, Yan Liu
Sylvester Comprehensive Cancer Center Professor of Medicine, Biochemistry & Molecular Biology,
University of Miami, USA (SDN), Indiana University School of Medicine, USA (YL)
Published in Atlas Database: December 2013
Online updated version : http://AtlasGeneticsOncology.org/Genes/ELF4ID42990chXq26.html
DOI: 10.4267/2042/53972
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology
Abstract
DNA/RNA
Review on ELF4, with data on DNA/RNA, on the
protein encoded and where the gene is implicated.
Description
Identity
The gene encompasses 45 kb of DNA; 9 exons.
The ELF4 gene contains 12 distinct gt-ag introns.
Transcription produces 5 alternatively spliced
mRNAs.
There are 2 probable alternative promoters, 2 non
overlapping alternative last exons and 2 validated
alternative polyadenylation sites.
The mRNAs appear to differ by truncation of the 3'
end, presence or absence of 3 cassette exons,
overlapping exons with different boundaries,
splicing versus retention of 2 introns.
Other names: ELFR, MEF
HGNC (Hugo): ELF4
Location: Xq26.1
Local order: The ELF4 gene maps on chomosome
X at position +1805468958720.00 (interpolated), at
Xq26 according to Entrez Gene. In AceView, it
covers 46,69 kb, from 129244687 to 129197994, on
the reverse strand.
The ELF4 gene is located on the X-chromosome (Xq26) and is transcribed from telomere to centromere. The ELF4 gene
contains 8 coding exons and 1 non-coding exon.
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7)
511
ELF4 (E74-like factor 4 (ets domain transcription factor))
Nimer SD, Liu Y
The ELF4 protein contains the following domains: (A) transactivation domain, (B) AML1 interacting domain, (C) ETS domain, (D)
serine/threonine rich region and (E) proline rich region.
Transcription
Localisation
4190 bp mRNA; 1991 bp open reading frame.
Nucleus, PML body. Accumulation into PML
nuclear bodies is mediated by PML (Suico et al.,
2004a; Suico et al., 2004b).
Pseudogene
No observed pseudogenes.
Function
Protein
ELF4 is a member of the ETS family of
transcription factors (TF) with transcription
activating properties (Lacorazza and Nimer, 2003).
ELF4 binds to DNA sequences containing the
consensus
5'-WGGA-3'
and
transactivates
promoters of the hematopoietic growth factor genes
CSF2, IL3, IL8, and of the bovine lysozyme gene
(Miyazaki et al., 1996; Mao et al., 1999; Hedvat et
al., 2004; Suico et al., 2004). ELF4 acts
synergistically with RUNX1 to transactivate the
IL3 promoter (Mao et al., 1999).
It also transactivates the PRF1 promoter in natural
killer (NK) cells (Lacorazza et al., 2002).
ELF4 has important molecular functions, including
protein binding, transcription activator activity,
sequence-specific DNA binding, transcription
factor activity. ELF4 interacts with multiple
proteins, including Cyclin A/CDK2 kinase
complex, FBXO4, FBXO7, PML, RUNX1, SKP2
and UBB (Miyazaki et al., 1996; Mao et al., 1999;
Miyazaki et al., 2001; Liu et al., 2006; Suico et al.,
2006).
Description
663 amino acids; 70730 Da protein; numerous
posttranslational modifications: phosphorylation,
sumoylation and ubiquitination (Miyazaki et al.,
2001; Liu et al., 2006; Suico et al., 2006). ELF4
contains, from N-term to C-term, transactivation
domain (53-86), AML1 interacting domain (87206), ETS domain (207-291), serine/threonine rich
region (306-347) and proline rich region (477-517)
(Miyazaki et al., 1996; Mao et al., 1999; Suico et
al., 2002; Lacorazza and Nimer, 2003).
Expression
Abundantly expressed in the placenta and in a
variety of myeloid leukemia cell lines. Moderate
levels of expression in heart, lung, spleen, thymus,
peripheral blood lymphocytes, ovary and colon.
Lower levels of expression in Jurkat T-cells and
other T-cell lines and no expression in brain
(Lacorazza and Nimer, 2003).
ELF4 interacts with multiple proteins and plays important role in development and oncogenesis.
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7)
512
ELF4 (E74-like factor 4 (ets domain transcription factor))
Nimer SD, Liu Y
ELF4 has been implicated in widely divergent
physiological and pathological processes (such as
development and oncogenesis).
ELF4 plays an important role in the development
and function of NK and NK T-cells and in innate
immunity (Lacorazza et al., 2002).
It controls the proliferation and homing of CD8+ Tcells via the Kruppel-like factors KLF4 and KLF2
(Yamada et al., 2009; Yamada et al., 2010).
ELF4 regulates hematopoietic stem cell quiescence
and self-renewal (Lacorazza et al., 2006; Liu et al.,
2009). ELF4 also regulates self-renewal of braintumor stem cells (Bazzoli et al., 2012).
In addition, ELF4 plays an important role in
osteogenic differentiation and bone development
(Kim et al., 2007; Seul et al., 2011; Baek et al.,
2012).
It mediates DNA damage response (Morales et al.,
2008; Sashida et al., 2011).
ELF4 controls cell senescence in a p53-dependent
manner and can also promote cellular
transformation through inhibition of the p16
pathway as well (Sashida et al., 2009).
ELF4, a member of the ETS transcription factors,
can function as an oncogene in murine cancer
models and is overexpressed in various human
cancers (Lacorazza and Nimer, 2003; Sashida et al.,
2010).
In addition to its oncogenic potential, ELF4 has
been proposed to be a candidate tumor suppressor
gene on the X chromosome (Seki et al., 2002).
Mutations
Note
No known mutations. Fused in hepatocellular
carcinoma with the BCORL1 gene.
Implicated in
Acute myeloid leukemia
Disease
Acute myeloid leukemia (AML) is the most
common acute leukemia in adults. It usually occurs
around age 60 with no identifiable cause and it
carries a very poor prognosis, with most patients
living less than 18 months. AML is a devastating
illness with over 13000 new diagnoses and 10000
patients dying annually in the United States.
Although select molecular subpopulations of
patients are long-term survivors, the overall fiveyear survival for adults is only 25%. ETS proteins
(such as PU.1, Fli-1 and ETS-1) have been shown
to play important roles in normal and abnormal
hematopoiesis (Lacorazza and Nimer, 2003). ELF1
and ELF4 were expressed in all AML samples,
whereas NERF was not. The relative expression of
ELF4, but not ELF1, was significantly lower
(P<0.0001) in AML with t(8;21) and t(15;17)
compared with AML with normal karyotype
(Fukushima et al., 2003; Ando et al., 2013).
Prognosis
The low relative expression of ELF4, might be part
of a gene expression profile characterizing AML
with a good prognosis (Fukushima et al., 2003;
Ando et al., 2013).
Cytogenetics
A chromosomal translocation has been reported in
AML, t(X;21)(q25-26;q22), that generates a fusion
transcript between two ETS family members, ELF4
(at Xq26) and ERG (at 21q22). The translocation
occurs within intron 1 of ERG isoform 1 (ERG-1)
and intron 2 of ELF4 resulting in an in-frame fusion
joining exon 2 from ELF4 with exon 2 of ERG
(Moore et al., 2006).
Hybrid/Mutated gene
ELF4-ERG. The fusion sequence includes exon 2
of ELF4 and exon 2 of ERG1, with the breakpoint
occurring after exon 2 in ELF4 (intron 2) and
before exon 2 of ERG1 (intron 1) (Moore et al.,
2006).
Abnormal protein
ELF4-ERG (495 amino acids).
Homology
The transcription factor ELF4 belongs to the ETS
family of transcription factors, named after the E26
(E twenty six) leukemogenic chicken virus which
contains a gag-myb-ets fusion.
These proteins are characterized by the presence of
the ETS domain (a conserved 84 amino acid
domain) that binds to a DNA consensus sequence
containing a GGAA central core via a winged
helix-turn-helix motif.
Based on the homology of the ETS domain, these
proteins have been classified in different
subfamilies (e.g., Elf, Spi, and Yan).
The ETS domain is highly conserved among family
members with the greatest homology of ELF4 with
other proteins in the Elf subfamily, which also
includes ELF1, NERF1a, and NERF1b. ELF4 does
not contain an HLH or pointed protein-protein
interaction domain, which is present in members of
the ETS, ERG, GABP, and Yan subfamilies
(Lacorazza and Nimer, 2003).
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7)
513
ELF4 (E74-like factor 4 (ets domain transcription factor))
Nimer SD, Liu Y
Horizontal lines represent amino acid residues for ELF4 and ERG-1. Numbers above each line indicate the number of amino
acids at the corresponding position. Boxes below indicate locations of the conserved domains within both protein sequences.
The predicted fusion protein would include the first 25 amino acid residues from ELF4 encoded by exon 2 and the last 470 amino
acid residues encoded by ERG exons 2-10 resulting in a protein of 495 amino acids. The conserved SAM-PNT and ETS
domains from ERG would be included in the fusion while the ETS domain from ELF4 would be excluded.
Overexpression of ELF4 in SKOV3 cells
significantly increased their growth rate, enhanced
colony formation in soft agar and promoted tumor
formation in nude mice. The oncogenic activity of
MEF was further shown by the ability of ELF4 to
transform NIH3T3 cells, and induce their tumor
formation in nude mice (Yao et al., 2007). Thus,
ELF4 is an important regulator of the tumorigenic
properties of ovarian cancer cells and could be used
a therapeutic target in ovarian cancer (Yao et al.,
2007).
Oncogenesis
ERG has been associated with other fusion partners,
specifically FUS and EWSR1, and implicated in
both AML and Ewing's sarcoma. The ELF4-ERG
fusion suggests a new role for ELF4 in
leukemogenesis and human cancer (Moore et al.,
2006), as it provides a strong promoter to express
ERG.
In addition, wild-type nucleophosmin (NPM1)
inhibits the DNA binding and transcriptional
activity of ELF4 on the HDM2 promoter, while a
common, leukemia-associated NPM1 mutant
protein (Mt-NPM1) enhances these activities of
ELF4 (Ando et al., 2013). Moreover, clinical
leukemia samples with NPM1 mutations have
higher human MDM2 (HDM2) mRNA expression.
These data suggest that enhanced HDM2
expression induced by mutant NPM1 may have a
role in ELF4-dependent leukemogenesis (Ando et
al., 2013).
Gliomas
Disease
Malignant gliomas represent the most prevalent
primary brain tumor in adults and inevitably have a
poor prognosis. Despite the implementation of new
therapeutic strategies, the median survival of
patients with glioblastoma multiforme (GBM), the
most aggressive glioma variant, is only 14-16
months and these tumors remain rapidly and
uniformly fatal. High-grade gliomas are composed
of a heterogeneous population of cells that include
many with stem-cell-like properties. The
acquisition of stem-like traits might contribute to
glioma initiation, growth, and recurrence. ELF4 is
highly expressed in both human and mouse
glioblastomas
and
its
absence
impairs
gliomagenesis in a PDGF-driven glioma mouse
model (Bazzoli et al., 2012).
Prognosis
High levels of ELF4 expression in gliomas are
associated with a poor prognosis (Bazzoli et al.,
2012).
Oncogenesis
Modulation of ELF4 levels in both mouse neural
stem cells and human glioblastoma cells has a
significant impact on neurosphere formation. Thus,
ELF4 is a gatekeeper gene that promotes stemness
in the pathogenesis of gliomas (Bazzoli et al.,
2012).
Ovarian cancer
Disease
Ovarian cancer is the seventh most common cancer
in women worldwide and the second leading cause
of death among the gynecological malignancies.
ELF4 is expressed in a significant proportion of
ovarian carcinomas, and in the CAOV3 and
SKOV3 ovarian cancer cell lines, but not in normal
ovarian surface epithelium (Yao et al., 2007).
Prognosis
High levels of ELF4 expression in ovarian cancer
are associated with a poor prognosis (Yao et al.,
2007).
Oncogenesis
Manipulating MEF levels in ovarian cancer cell
lines alters their behavior; reducing ELF4 levels,
using short hairpin RNA expressing vectors,
significantly inhibited the proliferation of SKOV3
and CAOV3 cells in culture, and impaired the
anchorage-independent growth of CAOV3 cells.
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7)
514
ELF4 (E74-like factor 4 (ets domain transcription factor))
Nimer SD, Liu Y
References
Elf4/myeloid Elf-1-like factor. Biochem Biophys Res
Commun. 2006 Sep 29;348(3):880-8
Miyazaki Y, Sun X, Uchida H, Zhang J, Nimer S. MEF, a
novel transcription factor with an Elf-1 like DNA binding
domain but distinct transcriptional activating properties.
Oncogene. 1996 Oct 17;13(8):1721-9
Kim YJ, Kim BG, Lee SJ, Lee HK, Lee SH, Ryoo HM, Cho
JY. The suppressive effect of myeloid Elf-1-like factor
(MEF) in osteogenic differentiation. J Cell Physiol. 2007
Apr;211(1):253-60
Mao S, Frank RC, Zhang J, Miyazaki Y, Nimer SD.
Functional and physical interactions between AML1
proteins and an ETS protein, MEF: implications for the
pathogenesis of t(8;21)-positive leukemias. Mol Cell Biol.
1999 May;19(5):3635-44
Yao JJ, Liu Y, Lacorazza HD, Soslow RA, Scandura JM,
Nimer SD, Hedvat CV. Tumor promoting properties of the
ETS protein MEF in ovarian cancer. Oncogene. 2007 Jun
7;26(27):4032-7
Morales M, Liu Y, Laiakis EC, Morgan WF, Nimer SD,
Petrini JH. DNA damage signaling in hematopoietic cells: a
role for Mre11 complex repair of topoisomerase lesions.
Cancer Res. 2008 Apr 1;68(7):2186-93
Miyazaki Y, Boccuni P, Mao S, Zhang J, ErdjumentBromage H, Tempst P, Kiyokawa H, Nimer SD. Cyclin Adependent phosphorylation of the ETS-related protein,
MEF, restricts its activity to the G1 phase of the cell cycle.
J Biol Chem. 2001 Nov 2;276(44):40528-36
Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y et al.. p53
regulates hematopoietic stem cell quiescence. Cell Stem
Cell. 2009 Jan 9;4(1):37-48
Lacorazza HD, Miyazaki Y, Di Cristofano A et al.. The ETS
protein MEF plays a critical role in perforin gene
expression and the development of natural killer and NK-T
cells. Immunity. 2002 Oct;17(4):437-49
Sashida G, Liu Y, Elf S, Miyata Y, Ohyashiki K, Izumi M,
Menendez S, Nimer SD. ELF4/MEF activates MDM2
expression and blocks oncogene-induced p16 activation to
promote
transformation.
Mol
Cell
Biol.
2009
Jul;29(13):3687-99
Seki Y, Suico MA, Uto A, Hisatsune A, Shuto T, Isohama
Y, Kai H. The ETS transcription factor MEF is a candidate
tumor suppressor gene on the X chromosome. Cancer
Res. 2002 Nov 15;62(22):6579-86
Yamada T, Park CS, Mamonkin M, Lacorazza HD.
Transcription factor ELF4 controls the proliferation and
homing of CD8+ T cells via the Krüppel-like factors KLF4
and KLF2. Nat Immunol. 2009 Jun;10(6):618-26
Suico MA, Koyanagi T, Ise S, Lu Z, Hisatsune A, Seki Y,
Shuto T, Isohama Y, Miyata T, Kai H. Functional dissection
of the ETS transcription factor MEF. Biochim Biophys Acta.
2002 Aug 19;1577(1):113-20
Sashida G, Bazzoli E, Menendez S, Liu Y, Nimer SD. The
oncogenic role of the ETS transcription factors MEF and
ERG. Cell Cycle. 2010 Sep 1;9(17):3457-9
Fukushima T, Miyazaki Y, Tsushima H et al.. The level of
MEF but not ELF-1 correlates with FAB subtype of acute
myeloid leukemia and is low in good prognosis cases.
Leuk Res. 2003 May;27(5):387-92
Yamada T, Gierach K, Lee PH, Wang X, Lacorazza HD.
Cutting edge: Expression of the transcription factor E74like factor 4 is regulated by the mammalian target of
rapamycin pathway in CD8+ T cells. J Immunol. 2010 Oct
1;185(7):3824-8
Lacorazza HD, Nimer SD. The emerging role of the
myeloid Elf-1 like transcription factor in hematopoiesis.
Blood Cells Mol Dis. 2003 Nov-Dec;31(3):342-50
Sashida G, Bae N, Di Giandomenico S, Asai T, Gurvich N,
Bazzoli E, Liu Y, Huang G, Zhao X, Menendez S, Nimer
SD. The mef/elf4 transcription factor fine tunes the DNA
damage response. Cancer Res. 2011 Jul 15;71(14):485765
Hedvat CV, Yao J, Sokolic RA, Nimer SD. Myeloid ELF1like factor is a potent activator of interleukin-8 expression
in hematopoietic cells. J Biol Chem. 2004 Feb
20;279(8):6395-400
Suico MA, Lu Z, Shuto T, Koga T, Uchikawa T et al.. The
regulation of human beta-defensin 2 by the ETS
transcription factor MEF (myeloid Elf-1-like factor) is
enhanced by promyelocytic leukemia protein. J Pharmacol
Sci. 2004a Aug;95(4):466-70
Seul KJ, Cho HS, Heo SH, Baek WY, Kim JE, Park EK,
Choi JY, Ryoo HM, Cho JY. Osteoblast-specific
expression of MEF induces osteopenia through
downregulation of osteoblastogenesis and upregulation of
osteoclastogenesis.
J
Bone
Miner
Res.
2011
Feb;26(2):341-50
Suico MA, Yoshida H, Seki Y, Uchikawa T et al.. Myeloid
Elf-1-like factor, an ETS transcription factor, up-regulates
lysozyme transcription in epithelial cells through interaction
with promyelocytic leukemia protein. J Biol Chem. 2004b
Apr 30;279(18):19091-8
Baek K, Cho JY, Hwang HR, Kwon A et al.. Myeloid Elf-1like factor stimulates adipogenic differentiation through the
induction of peroxisome proliferator-activated receptor γ
expression in bone marrow. J Cell Physiol. 2012
Nov;227(11):3603-12
Lacorazza HD, Yamada T, Liu Y, Miyata Y, Sivina M,
Nunes J, Nimer SD. The transcription factor MEF/ELF4
regulates the quiescence of primitive hematopoietic cells.
Cancer Cell. 2006 Mar;9(3):175-87
Bazzoli E, Pulvirenti T, Oberstadt MC et al.. MEF promotes
stemness in the pathogenesis of gliomas. Cell Stem Cell.
2012 Dec 7;11(6):836-44
Liu Y, Hedvat CV, Mao S, Zhu XH, Yao J, Nguyen H, Koff
A, Nimer SD. The ETS protein MEF is regulated by
phosphorylation-dependent proteolysis via the proteinubiquitin ligase SCFSkp2. Mol Cell Biol. 2006
Apr;26(8):3114-23
Ando K, Tsushima H, Matsuo E, Horio K et al.. Mutations
in the nucleolar phosphoprotein, nucleophosmin, promote
the expression of the oncogenic transcription factor
MEF/ELF4
in
leukemia
cells
and
potentiates
transformation. J Biol Chem. 2013 Mar 29;288(13):945767
Moore SD, Offor O, Ferry JA, Amrein PC, Morton CC, Dal
Cin P. ELF4 is fused to ERG in a case of acute myeloid
leukemia with a t(X;21)(q25-26;q22). Leuk Res. 2006
Aug;30(8):1037-42
This article should be referenced as such:
Nimer SD, Liu Y. ELF4 (E74-like factor 4 (ets domain
transcription factor)). Atlas Genet Cytogenet Oncol
Haematol. 2014; 18(7):511-515.
Suico MA, Nakamura H, Lu Z, Saitoh H, Shuto T, Nakao
M, Kai H. SUMO down-regulates the activity of
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7)
515